In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.
This Content Component encountered an error

More research urgently needed to treat and prevent cardiovascular disease

European Society of Cardiology
Risk Factors and Prevention


Sophia Antipolis, 15 April 2019:  Heart disease remains the world’s leading cause of death, and today top European scientists outlined their battle plans for the coming years, calling for more investment in research.

This call-to-action was produced by the EU-funded ERA–CVD, a coalition of 24 partners including the European Society of Cardiology (ESC).1

“In spite of Cardiovascular Disease (CVD) remaining the main cause of death globally, research - and new medicines available to patients - have declined over the last ten years. Innovative methods and more clinical trials in cardiology are required to ensure that we can address the vast unmet needs we see today,” said Professor Tomasz Guzik, Chair of the ESC Research and Grants Committee.  “We need to detect CVD earlier and avoid acute events that lead to irreversible damage and chronic illness. A strategic research agenda for CVD at the European level will help ensure that research efforts and investment are directed at the most pressing questions.”

CVDs cause more death and disability than cancer – 4 million compared to 2.1 million deaths in 2016 – yet funding for CVD research lags behind. Oncology has the largest share of health and biomedical papers at 23%, compared to just 10% for CVD, suggesting less research activity.

 “There is false optimism that cardiovascular disease (CVD) is no longer a public health problem,” states the report. In Europe, more than 10,000 patients die of CVD every day. CVD is expected to remain the top reason for death, premature death and disease burden in Europe over the next 20 years.

The document proposes 15 topics for CVD research in three categories: prevention strategies; treatment and management; and living with chronic cardiovascular diseases.

 

Among the topics are:

  • Can wearables help people improve and maintain a healthy lifestyle?
  • How to anticipate and prevent heart attack, cardiac arrest, and stroke.
  • Using data on genetics, physical and mental health, and socioeconomic status to tailor risk assessment, lifestyle advice, and preventive treatment.
  • How CVD interacts with cancer and diabetes and the potential for combined treatments.
  • Clarifying the biological, behavioural, and social mechanisms of CVD in women versus men.
  • Understanding the crosstalk between cognitive decline and CVD to jointly tackle both conditions.
  • Ways to support CVD patients with depression, anxiety, and extreme tiredness.
  • What CVD patients and caregivers need and expect from healthcare providers at the end of life.
  • Research on new advanced cell-derived therapies to detain the progression of acute heart disease to heart failure

ERA–CVD is set to launch an online survey for patients, the public, healthcare providers, and research scientists to rank the 15 topics. It will be available here: https://enquetes.agencerecherche.fr/index.php/survey/index/sid/478641/lang/en

Implementation of the proposed research agenda will require action at EU and national level from ministries, funding agencies, healthcare administrators, and the private sector.

“The burden of CVD is immense and greater than any other condition, yet it receives less research funding,” said Professor Lina Badimon, Chair of the ESC Advocacy Committee. “As the next EU framework programme for research ‘Horizon Europe’ is developed, we call on EU decision-makers to act on this discrepancy by prioritising CVD research. The ERA–CVD Strategic Research Agenda provides a blueprint on how to combat CVDs through basic and translational research.”

ENDS

 

Notes to editor

Authors: ESC Press Office
Tel: +33 (0)4 8987 2499
Mobile: +337 (0) 8531 2036
Email: press@escardio.org

Follow us on Twitter @ESCardioNews 

Funding: None.

Disclosures: None.

 

References

1The Strategic Research Agenda SRA-CVD: “Challenges and Opportunities for Cardiovascular Disease Research” (2019). https://www.escardio.org/The-ESC/Advocacy/Partnerships/esc-pushing-for-more-eu-research-funding


About the European Society of Cardiology

The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

 

About ERA-CVD

ERA-CVD is a European Research Area Network (ERA-Net) comprising 24 partners from 19 countries/regions that has been granted funding through the current EU Framework Programme for Research and Innovation ‘Horizon 2020’ under grant agreement no [680969].